- Home
- FGF vs AKTX Comparison
FGF vs AKTX Comparison
Compare FGF & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- AKTX
- Stock Information
- Founded
- FGF 2012
- AKTX N/A
- Country
- FGF United States
- AKTX United States
- Employees
- FGF N/A
- AKTX N/A
- Industry
- FGF Property-Casualty Insurers
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- AKTX Health Care
- Exchange
- FGF Nasdaq
- AKTX Nasdaq
- Market Cap
- FGF 20.9M
- AKTX 41.8M
- IPO Year
- FGF N/A
- AKTX N/A
- Fundamental
- Price
- FGF $16.01
- AKTX $1.17
- Analyst Decision
- FGF
- AKTX
- Analyst Count
- FGF 0
- AKTX 0
- Target Price
- FGF N/A
- AKTX N/A
- AVG Volume (30 Days)
- FGF 3.5K
- AKTX 28.8K
- Earning Date
- FGF 08-13-2025
- AKTX 08-18-2025
- Dividend Yield
- FGF N/A
- AKTX N/A
- EPS Growth
- FGF N/A
- AKTX N/A
- EPS
- FGF N/A
- AKTX N/A
- Revenue
- FGF $13,260,000.00
- AKTX N/A
- Revenue This Year
- FGF N/A
- AKTX N/A
- Revenue Next Year
- FGF N/A
- AKTX N/A
- P/E Ratio
- FGF N/A
- AKTX N/A
- Revenue Growth
- FGF N/A
- AKTX N/A
- 52 Week Low
- FGF $14.21
- AKTX $0.85
- 52 Week High
- FGF $38.40
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- FGF 37.21
- AKTX 44.98
- Support Level
- FGF $16.50
- AKTX $1.15
- Resistance Level
- FGF $18.87
- AKTX $1.22
- Average True Range (ATR)
- FGF 0.47
- AKTX 0.08
- MACD
- FGF -0.08
- AKTX -0.00
- Stochastic Oscillator
- FGF 2.68
- AKTX 40.86
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.